5 completed, 2 active not recruiting, 1 withdrawn. 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 5, Active not recruiting 2, Withdrawn 1 |
Follow MF59: new trials by email Literature Review of MF59 trials Research Report on MF59
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older Subunit Influenza Vaccine (Adjuvant), MF59, 0.9% sodium chloride injection (normal saline) - Influenza, Influenza Vaccine | Phase 1 | Active not recruiting | Ab&B Bio-tech Co., Ltd.JS | 80 | 2025-11-13 | 2026-02-19 |
| Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older Quadrivalent Subunit Influenza Vaccine (Adjuvant), MF59, 0.9% sodium chloride injection (normal saline) - Influenza, Influenza Vaccine | Phase 1 | Active not recruiting | Ab&B Bio-tech Co., Ltd.JS | 80 | 2025-11-13 | 2026-02-19 |
| H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology AS03, MF59, Monovalent Influenza A/H5N8 vaccine - Avian Influenza | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 388 | 2017-01-09 | 2024-09-23 |
| Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo) MF59, rgp120/HIV-1 SF-2 - HIV Infections, Pregnancy | Phase 1 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-11-01 | ||
| A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203), Aluminum hydroxide, MF59 - HIV Infections, HIV Seronegativity | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 27 | 2021-10-28 | |
| A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals Aluminum hydroxide, Lipid A, Monophosphoryl, Lipid A, Liposome-encapsulated monophosphoryl - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 112 | 2021-11-04 | |
| A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers MF59, rgp120/HIV-1 SF-2 - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2021-11-04 | |
| A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3 Aluminum hydroxide, MF59, rgp120/HIV-1IIIB - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 130 | 2021-11-04 |
HIV Infections (5) · Influenza, Human (3) · AIDS-Related Complex (2) · Influenza in Birds (1) · Pregnancy Complications, Infectious (1)
National Institute of Allergy and Infectious Diseases (NIAID) (6) · Ab&B Bio-tech Co., Ltd.JS (2)
United States (5) · China (2)
Yeqing Tong, Doctor (2) · Allen M (1) · Corey L (1) · D Schwartz (1) · M Clements (1) · McElrath J (1) · Schooley RT (1) · Scott GB (1) · Silverman N (1) · Starr S (1) · Walker B (1)